Japan Drug Makers Facing Patent Cliff Turn To Biotech Drugs
This article was originally published in PharmAsia News
Executive SummarySeveral Japanese drug makers are betting on bioengineered drugs, with at least one awaiting regulatory approval, to counter the loss of patent protection for current blockbusters
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.